This shift towards higher RT doses per fraction for select patients with stage IV NSCLC has been supported by mouse models wherein higher RT doses in fewer fractions were associated with increased tumor CD8+ T-cell infiltration [27, 28]. Here, CD8A is linked to neoplasm.